Open AccessUsefulness of Procalcitonin in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Author(s) -
Donna Ann Cheung,
Leonardo Tamariz,
Zsuzsanémeth,
Amber Langshaw
Publication year - 2019
Publication title -
crohn's and colitis 360
Language(s) - English
Resource type - Journals
ISSN - 2631-827X
DOI - 10.1093/crocol/otz032
Subject(s) - procalcitonin , medicine , inflammatory bowel disease , meta analysis , gastroenterology , crohn's disease , disease , inflammatory bowel diseases , strictly standardized mean difference , sepsis
Background Mixed results are reported for procalcitonin (PCT) as biomarkers of infection and disease activity in inflammatory bowel disease (IBD). Method We systematically evaluated and performed a meta-analysis on the usefulness of PCT in assessing infection and disease activity in IBD. Results The pooled standardized mean difference of PCT for those with infection compared with those without was 1.59 (95% CI, 0.72–2.46, P < 0.01) and those with active disease compared with those without was 1.22 (95% CI, 0.66–1.78, P < 0.01), respectively. Conclusion PCT may potentially be useful in differentiating an infectious process from IBD and active from inactive IBD.